Biohaven Pharmaceutical (NYSE:BHVN) Issues Quarterly Earnings Results, Misses Expectations By $0.45 EPS

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) announced its earnings results on Tuesday. The company reported ($2.97) EPS for the quarter, missing the consensus estimate of ($2.52) by ($0.45), MarketWatch Earnings reports. During the same quarter last year, the firm posted ($4.21) earnings per share.

Shares of NYSE BHVN traded up $0.84 during trading on Wednesday, reaching $140.84. The stock had a trading volume of 362,151 shares, compared to its average volume of 904,966. The firm’s 50 day moving average price is $112.18 and its two-hundred day moving average price is $121.07. Biohaven Pharmaceutical has a one year low of $65.24 and a one year high of $151.51. The stock has a market cap of $9.93 billion, a PE ratio of -10.77 and a beta of 1.20.

Several institutional investors have recently bought and sold shares of the company. JustInvest LLC grew its holdings in shares of Biohaven Pharmaceutical by 16.3% during the fourth quarter. JustInvest LLC now owns 2,645 shares of the company’s stock valued at $365,000 after purchasing an additional 370 shares during the last quarter. BlackRock Inc. boosted its position in Biohaven Pharmaceutical by 0.6% during the 4th quarter. BlackRock Inc. now owns 4,635,280 shares of the company’s stock valued at $638,787,000 after purchasing an additional 28,207 shares during the period. Deutsche Bank AG grew its stake in Biohaven Pharmaceutical by 8.1% during the 4th quarter. Deutsche Bank AG now owns 797,980 shares of the company’s stock worth $109,969,000 after buying an additional 60,009 shares during the last quarter. California State Teachers Retirement System increased its position in Biohaven Pharmaceutical by 2.6% in the fourth quarter. California State Teachers Retirement System now owns 80,127 shares of the company’s stock worth $11,042,000 after buying an additional 2,009 shares during the period. Finally, Advisors Asset Management Inc. lifted its stake in Biohaven Pharmaceutical by 0.8% in the fourth quarter. Advisors Asset Management Inc. now owns 25,051 shares of the company’s stock valued at $3,452,000 after buying an additional 191 shares during the last quarter. Institutional investors own 88.03% of the company’s stock.

BHVN has been the topic of a number of analyst reports. SVB Leerink lowered shares of Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 price objective on the stock. in a research note on Wednesday. Mizuho boosted their price objective on shares of Biohaven Pharmaceutical from $144.00 to $154.00 and gave the stock a “buy” rating in a report on Thursday, March 3rd. Morgan Stanley lowered their target price on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. Finally, HC Wainwright downgraded Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $152.36.

About Biohaven Pharmaceutical (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Articles

Earnings History for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.